Eisai Plans Halaven Sarcoma Filings On New Data
This article was originally published in PharmAsia News
Executive Summary
Eisai sees its Halaven as a critical component of its strategic move into oncology, and its plans for the drug are moving forward after new late-stage clinical results for the microtubule dynamics inhibitor in a rare tumor type.